Top Biotech Companies in Washington, DC (37)
.png)
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop and commercialize pioneering products.
GRAIL's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising at a double‑digit pace across 2025 and into 2026, with consistent year‑over‑year gains. Galleri test volumes and screening revenue also increased, signaling sustained commercial momentum.
Market Expansion: Access is broadening through major EHR integrations and a growing provider network, alongside initiatives to enter new geographies. These moves extend reach beyond core channels and support continued adoption.
Investor Backing & Capital Strength: Capital raises and a sizable cash position provide a multi‑year runway to fund commercialization, trials, and regulatory efforts. Strategic financings with prominent partners reinforce the ability to invest through scale‑up.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.
Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.
Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.
Computercraft, an American Indian– and Woman-owned small business, provides the public with user-friendly access to reliable and current genetic sequence, genomic, chemical, and scientific information. Our technical and scientific staff work with customers to build and refine high-profile information resources that get accurate health and biomedical research data into the hands of researchers and other stakeholders all over the globe, helping...
Drug Information Association (DIA) is a leading global multidisciplinary life science membership association. It mobilizes life science professionals across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment. DIA focuses on the discovery, development, regulation, surveillance, and marketing of healthcare products to advance the life sciences community.
We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.
AstraZeneca's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue is rising strongly, with 2024 up to $54.1B and continued momentum into 2025 alongside management’s stated 2030 ambition. The trend is broad‑based across oncology and biopharma, with repeated beats and reaffirmed guidance supporting durability.
Strong Market Position & Advantage: Market position is top‑tier globally by value and leadership is pronounced in oncology, where the company ranks among the top three by revenue with multiple anchor assets. Scale and execution in the U.S. and other key markets underline competitive advantage.
Innovation-Driven Growth: Pipeline and approvals are driving expansion, with multiple 2025 U.S. FDA wins for ADCs, an expanded first‑line label for Enhertu, and a deep ASCO 2025 presence across ADC, I/O, targeted agents, and SERD.
At Elekta, our outcome-driven and cost-efficient solutions provide lasting clinical difference and are developed through sustainable environmental, social and governance practices. We’ve been working openly and proactively with clinicians and our partners for almost half a century to advance precision radiation therapy and meet continuously evolving patient needs—no matter where they are in the world. To us, it's personal, and...
Elekta's Top Stability & Growth Strengths
Strong Market Position & Advantage: Elekta is a top-tier radiotherapy vendor with category leadership in cranial stereotactic radiosurgery and a notable presence in high-field MR-guided therapy, reinforcing durable competitive standing. Recognition for oncology information systems further supports its positioning in cancer centers.
Innovation-Driven Growth: Recent launches such as Elekta Evo and the Elekta ONE software suite, alongside continued advancement of Unity MR‑Linac workflows, indicate a pipeline that is aiding orders and improving mix. These innovations underpin adaptive and image‑guided therapy strategies across the portfolio.
Resilient & Sustainable Growth: Book‑to‑bill ratios above 1.0 and low single‑digit constant‑currency sales growth point to steady underlying expansion. Improving adjusted margins in recent quarters suggest operational gains despite macro headwinds.
SNA International is a professional-services provider that applies advanced science, technology, and organizational expertise to high-consequence government missions. Its work spans forensic science, biometrics, human identification, genealogy, public-health preparedness, emergency response, identity and weapons technical intelligence, and CBRNE/CWMD support. SNA also develops technology such as DNAConnect, which connects forensic laboratories and law-enforcement personnel to support Rapid DNA operations and actionable...
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the...
Avalere Health's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.
Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.
Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to...
QIAGEN's Top Stability & Growth Strengths
Strong Market Position & Advantage: Leadership in latent TB blood testing (QuantiFERON) and entrenched sample‑preparation technologies is reinforced by global guidelines and deep workflow stickiness. The company is also building share in digital PCR and competes credibly in syndromic panels despite strong incumbents.
Resilient & Sustainable Growth: Net sales grew in 2025 with guidance for further mid‑single‑digit growth in 2026, and earnings are guided to improve. Growth is increasingly driven by non‑COVID ‘pillars’ with recurring consumables and software that generally support steadier demand.
Future-Ready Strategy: Management pruned non‑core lines (e.g., NeuMoDx exit) and refocused investment on five growth pillars with multi‑year targets through 2028. Ongoing menu expansions, regulatory submissions, and targeted M&A (e.g., single‑cell and clinical genomics software) indicate continued positioning for scaled, profitable growth.
We Engineer Solutions for the Nation’s Toughest Problems As an independent nonprofit engineering innovation company, Draper provides engineering services directly to government, industry, and academia. We work on teams as prime contractors or subcontractors and participate as collaborators in consortia. Our strong commitment to delivering working solutions allows us to apply ourselves to a variety of domains from space to undersea —...
We're hiring! ZERO TO THREE is a national nonprofit organization that informs, trains and supports professionals, policymakers and parents in their efforts to improve the lives of infants and toddlers. Neuroscientists have documented that our earliest days, weeks and months of life are a period of unparalleled growth when trillions of brain cell connections are made. Research and clinical experience...
Xylem |ˈzīləm| 1) The tissue in plants that brings water upward from the roots; 2) a leading global water technology company. Xylem, a leading global water technology company dedicated to solving the world’s most challenging water issues, is the leading global provider of efficient, innovative and sustainable water technologies improving the way water is used, managed, conserved and re-used. Our international team is...
Founded in 1967, Riverside Research is a not-for-profit organization chartered to advance scientific research for the benefit of the US government and in the public interest. Through our open innovation concept, we invest in multi-disciplinary research and development and encourage collaboration to accelerate innovation and advance science. Riverside Research conducts independent research in machine learning, trusted systems, optics and photonics,...
Founded in 1995, Meso Scale Discovery (MSD) is a global leader in the development, manufacture, and commercialization of innovative assays and instruments for the measurement of molecules in biological samples. MSD’s proprietary MULTI ARRAY technology enhances medical research and drug development by enabling researchers to profile many biomarkers simultaneously in a single sample without compromising assay performance. MSD’s technology has...
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for...
LGC's Top Stability & Growth Strengths
Strong Market Position & Advantage: Holding the UK’s National Measurement Laboratory designation and Government Chemist role, plus leading positions in reference materials, proficiency testing, and agrigenomics/genotyping, reinforces defensible niche leadership. Acquisitions and widespread adoption of technologies like KASP genotyping underscore recognized authority in core segments.
Strong Revenue Growth: Reported revenue increased year over year in FY25, reversing the prior year’s dip. Adjusted EBITDA also rose, indicating improved top-line momentum alongside better operating results.
Future-Ready Strategy: Large-scale site expansions (Toronto, Guildford, Berlin) and integration of recent acquisitions point to capacity build-out and a scale-focused operating model. A new CEO, business-unit consolidation, and an Innovation Hub signal intent to sustain growth through portfolio development and execution.
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company committed to excellence in the research, development, and commercialization of prescription medicines. With approximately 90,000 employees across 85 countries, the company aims to unlock the power of science to deliver innovative medicines that transform patient outcomes and improve healthcare for people, society, and the planet worldwide.
Danaher is a global science and technology innovator committed to helping their customers solve complex challenges and improve quality.
Sabin Vaccine Institute is a global nonprofit organization dedicated to making vaccines more accessible, enabling innovation, and expanding immunization across the globe. It develops impactful vaccines for unmet medical needs, fuels actionable research, champions data-driven advocacy, and strengthens immunization leadership, particularly in low- and middle-income countries, to protect the world's most vulnerable populations from vaccine-preventable infectious diseases.
PPD is now part of Thermo Fisher Scientific, the world leader in serving science. Together, Thermo Fisher and PPD are creating a unique opportunity to advance their shared pursuit to enable customers to make the world healthier by accelerating the development of new medicines. We now offer a comprehensive suite of world-class services across the clinical development spectrum – from...
54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and...
